We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic ICMs Detect High Rate of AF in Undiagnosed Patients
Read MoreHide Full Article
Medical device major Medtronic plc (MDT - Free Report) recently unveiled results from a new clinical study evaluating Insertable Cardiac Monitors (ICMs). These devices detect high incidence of atrial fibrillation (AF) in patients previously undiagnosed but suspected to be at high-risk for AF and stroke. The company recently presented the REVEAL AF (Incidence of AF in High Risk Patients) study at Heart Rhythm Society’s 38th Annual Scientific Sessions.
Over the last three months, Medtronic has been trading above the Zacks categorized Medical - Products industry. The stock has gained 7.4%, compared to 5.8% of the broader industry. We expect the latest REVEAL AF dataset to enhance heart failure business prospects and boost the company’s share price further.
Notably, AF is a common cardiac condition in which the heart beats irregularly or rapidly. Patients with AF are five times more likely to have a stroke due to small blood clots that may form in the heart and subsequently travel to the brain. Failure to recognize and treat AF can lead to strokes because AF often has no symptoms. This condition is also difficult to be detected using conventional cardiac monitoring techniques such as in-hospital monitoring, electrocardiography or traditional ambulatory cardiac monitors.
However, Medtronic’s latest Reveal LINQ ICM with TruRhythm Detection can automatically and continuously detect and record abnormal heart rhythms for up to three years. The company received U.S. FDA 510(k) clearance for this particular device earlier this year. The ICM device is inserted using a minimally invasive procedure and its presence is often nearly undetectable to the naked eye. The device communicates wirelessly with a patient’s bedside monitor that uploads device data to the Medtronic CareLink network.
In details, REVEAL AF is a prospective study for evaluating the incidence of AF that lasted six minutes or more in high-risk patients who were previously undiagnosed with AF. The study found that continuous monitoring with either the Reveal XT ICM or the Reveal LINQ ICM resulted in an AF detection rate of 29.3% among previously undiagnosed high-risk patients. The Reveal AF study also evaluated how physicians managed patients when AF was found. More than half of the patients detected with AF were prescribed oral anticoagulation by their physicians, which have been shown to significantly reduce the risk of a stroke. This suggests that the information provided by the Reveal ICM was clinically meaningful.
As per a report by GlobalData, the global heart failure market is set to reach a worth of $11.8 billion by 2025, at a CAGR of 13.7%. Over more than a year, a gradually stabilizing trend is being observed in the global heart failure market, given the huge and growing market for minimally invasive procedures.
Zacks Rank & Key Picks
Medtronic carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector are Luminex Corporation , Hologic, Inc. (HOLX - Free Report) and Sunshine Heart Inc . Notably, Hologic and Luminex sport a Zacks Rank #1 (Strong Buy), while Sunshine Heart carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 15.4% over the last three months.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a solid one-year return of roughly 25%.
Sunshine Heart recorded a stellar EPS growth rate of almost 22% (last 3–5 years of actual earnings).
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic ICMs Detect High Rate of AF in Undiagnosed Patients
Medical device major Medtronic plc (MDT - Free Report) recently unveiled results from a new clinical study evaluating Insertable Cardiac Monitors (ICMs). These devices detect high incidence of atrial fibrillation (AF) in patients previously undiagnosed but suspected to be at high-risk for AF and stroke. The company recently presented the REVEAL AF (Incidence of AF in High Risk Patients) study at Heart Rhythm Society’s 38th Annual Scientific Sessions.
Over the last three months, Medtronic has been trading above the Zacks categorized Medical - Products industry. The stock has gained 7.4%, compared to 5.8% of the broader industry. We expect the latest REVEAL AF dataset to enhance heart failure business prospects and boost the company’s share price further.
Notably, AF is a common cardiac condition in which the heart beats irregularly or rapidly. Patients with AF are five times more likely to have a stroke due to small blood clots that may form in the heart and subsequently travel to the brain. Failure to recognize and treat AF can lead to strokes because AF often has no symptoms. This condition is also difficult to be detected using conventional cardiac monitoring techniques such as in-hospital monitoring, electrocardiography or traditional ambulatory cardiac monitors.
However, Medtronic’s latest Reveal LINQ ICM with TruRhythm Detection can automatically and continuously detect and record abnormal heart rhythms for up to three years. The company received U.S. FDA 510(k) clearance for this particular device earlier this year. The ICM device is inserted using a minimally invasive procedure and its presence is often nearly undetectable to the naked eye. The device communicates wirelessly with a patient’s bedside monitor that uploads device data to the Medtronic CareLink network.
Medtronic PLC Price
Medtronic PLC Price | Medtronic PLC Quote
In details, REVEAL AF is a prospective study for evaluating the incidence of AF that lasted six minutes or more in high-risk patients who were previously undiagnosed with AF. The study found that continuous monitoring with either the Reveal XT ICM or the Reveal LINQ ICM resulted in an AF detection rate of 29.3% among previously undiagnosed high-risk patients. The Reveal AF study also evaluated how physicians managed patients when AF was found. More than half of the patients detected with AF were prescribed oral anticoagulation by their physicians, which have been shown to significantly reduce the risk of a stroke. This suggests that the information provided by the Reveal ICM was clinically meaningful.
As per a report by GlobalData, the global heart failure market is set to reach a worth of $11.8 billion by 2025, at a CAGR of 13.7%. Over more than a year, a gradually stabilizing trend is being observed in the global heart failure market, given the huge and growing market for minimally invasive procedures.
Zacks Rank & Key Picks
Medtronic carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector are Luminex Corporation , Hologic, Inc. (HOLX - Free Report) and Sunshine Heart Inc . Notably, Hologic and Luminex sport a Zacks Rank #1 (Strong Buy), while Sunshine Heart carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock added roughly 15.4% over the last three months.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a solid one-year return of roughly 25%.
Sunshine Heart recorded a stellar EPS growth rate of almost 22% (last 3–5 years of actual earnings).
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>